Injunction Against Pfizer's Exubera Tossed Out

Law360, New York (December 14, 2006, 12:00 AM EST) -- A federal judge dealt healthcare company Novo Nordisk A/S a blow Thursday, denying the company’s bid for a preliminary injunction that would have barred sales of Pfizer Inc.’s inhaled insulin product Exubera.

U.S. District Judge Leonard B. Sands’ ruling came in the context of Novo Nordisk’s patent suit against Pfizer, which was filed in August. The suit accuses Pfizer of infringing five patents dealing with insulin through its sales of Exubera as a treatment for diabetes.

Novo Nordisk is still looking forward to a trial on...
To view the full article, register now.